Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 140

Results For "India"

3241 News Found

Laurus Labs inks JV agreement with KRKA, Slovenia
News | January 26, 2024

Laurus Labs inks JV agreement with KRKA, Slovenia

The registered capital of the newly founded company is € 50 million


Roche inaugurates new campus for Digital Centre of Excellence in Pune
News | January 26, 2024

Roche inaugurates new campus for Digital Centre of Excellence in Pune

The new campus has been designed as an employee-centred experience and ecosystem zone


Health Minister Mandaviya inaugurates super specialty block at GSVM Medical College in UP
Healthcare | January 25, 2024

Health Minister Mandaviya inaugurates super specialty block at GSVM Medical College in UP

Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur


Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr
News | January 25, 2024

Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr

Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023


Aster DM Healthcare gets shareholders nod to separate the GCC business
News | January 24, 2024

Aster DM Healthcare gets shareholders nod to separate the GCC business

The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years


Lupin receives USFDA’s approval for Febuxostat Tablets
Drug Approval | January 19, 2024

Lupin receives USFDA’s approval for Febuxostat Tablets

Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)


Zydus receives USFDA’s approvals for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg
Drug Approval | January 18, 2024

Zydus receives USFDA’s approvals for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg

Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis


NATCO invests US$ 2 million in Cellogen Therapeutics
News | January 18, 2024

NATCO invests US$ 2 million in Cellogen Therapeutics

Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy


Indoco Remedies receives EIR from USFDA for Goa Plant-I
Drug Approval | January 18, 2024

Indoco Remedies receives EIR from USFDA for Goa Plant-I

The PAI was conducted for two drug product applications (ANDAs) filed from this facility